Filing Flows

Filing Flows › Companies › Apyx Medical › Report card

Apyx Medical earnings report card

Every report on file against what analysts and the company itself expected, and what the stock did

Beat rate5 of 5 reports beat the EPS estimate

Apyx Medical (APYX) beat the analysts' EPS estimate in 5 of its last 5 reports (100%), by +44.8% on average.

Beat rate100% of 5
Average surprise+44.8%

Report by report

QuarterReportedEPS est.EPS reportedSurpriseRevenue reported
Q3 2026Nov 5, 2026−$0.09−$0.04+57.1%$14.0M
Q2 2026Aug 6, 2026−$0.08−$0.07+14.6%$13.9M
Q1 2026May 7, 2026−$0.11−$0.05+54.5%$12.5M
Q4 2025Mar 10, 2026−$0.06−$0.03+46.4%$19.2M
Q3 2025Nov 6, 2025−$0.10−$0.05+51.2%$12.9M

Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. No daily prices are on file for these report days, so the stock's moves are not shown.

Charts

Apyx Medical: EPS reported against the estimateApyx Medical: EPS reported against the estimateEstimateReported−$0.10−$0.05Q3 2025−$0.06−$0.03Q4 2025−$0.11−$0.05Q1 2026−$0.08−$0.07Q2 2026−$0.09−$0.04Q3 2026
Latest (Q3 2026): Estimate −$0.09, Reported −$0.04.

The next report: what to expect → Apyx Medical: every quarter →

Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.